← The Wire
CGENNasdaq
COMPUGEN LTD
Biological Products, (No Diagnostic Substances) · L3 · CIK 1119774
Compugen Ltd. discovers and develops cancer immunotherapies using its AI/ML platform
$193M
Market cap
$2.16
Last close
+3.4%
1D
+4.3%
5D
257K
Volume
Price · last 39 sessions-18.2%
May 4L $1.96 · H $3.03Jun 29
435
Total filings
May 18, 2026
Last filing
12/31
Fiscal year end
SC 13GSC 13GSep 9, 2019SC 13GSC 13GSep 6, 2019SC 13GSC 13GFeb 14, 2019SC 13GCOMPUGEN LIMITEDJun 22, 2018SC 13GSCHEDULE 13GFeb 14, 2017SC 13GSC 13GFeb 1, 2017SC 13GSC 13GMar 12, 2012SC 13GSCHEDULE 13GFeb 12, 2010SC 13GSC 13GMar 10, 2009SC 13GCOMPUGEN LTDFeb 13, 2009SC 13GCOMPUGENFeb 10, 2009SC 13GSC 13GDec 22, 2008SC 13GSC 13G - MARTIN GERSTEL - MAY 7, 2007May 7, 2007SC 13GFORM SC 13G MARTIN GERSTEL 2005 - FEBRUARY 6, 2006Feb 6, 2006SC 13GSC13G MARTIN S. GERSTELFeb 14, 2005SC 13GSC13G MARTIN S. GERSTELFeb 17, 2004SC 13GSC 13GFeb 10, 2004SC 13GSC 13GDec 10, 2003SC 13GSC 13GDec 9, 2002SC 13GSC 13GFeb 14, 2002SC 13GAUTO-GENERATED PAPER DOCUMENTFeb 1, 2002SC 13GINITIAL FILINGFeb 14, 2001SC 13GFORM SC 13GFeb 13, 2001
Insider Activity
In the 90 days to Mar 26, 2026: 1 sold $24K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 26, 2026 | Levine ZuritSVP, Business Development | Sell | 11,875 | $2.04 | $24K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance